Hims & Hers Stock Rises 5% After Adding Zepbound And Mounjaro To Weight Loss Platform

Benzinga

Hims & Hers Health shares rose 5% Tuesday after announcing it will offer Eli Lilly’s Zepbound and Mounjaro through its weight loss platform, according to CNBC.  Weight loss drugs have surged in popularity in recent years, and Hims & Hers added these to its weight loss program while navigating supply and regulatory challenges. A Lilly spokesperson said the company has no affiliation with Hims & Hers and noted that Zepbound may be cheaper for insured patients or those who buy directly.

Transcript

00:00It's Benzinga bringing Wall Street to Main Street.

00:02Health shares rose 5% Tuesday after announcing it will offer Eli Lilly's ZepBound and Monjarno

00:07through its weight loss platform, according to CNBC.

00:10They lost drugs of surge in popularity in recent years, and Hims and Hers added these

00:14to its weight loss program while navigating supply and regulatory challenges.

00:18A Lilly spokesperson said the company has no affiliation with Hims and Hers

00:22and noted that ZepBound may be cheaper for insured patients or those who buy directly.

00:26For all things money, visit Benzinga.com slash GSTV.

Category

Transcript

Comments

Recommended